Strategic partnerships Ryvu has a track record of 11 partnering and licensing deals with global players (e.g., Merck, Menarini, Galapagos, Exelixis, BioNTech), indicating a receptive environment for collaboration and licensing opportunities to accelerate clinical programs.

Clinical pipeline leverage Leading programs like RVU120 (CDK8/CDK19 inhibitor) and SEL24 (PIM/FLT3 inhibitor) are in active clinical development across hematologic and solid tumors, suggesting opportunities to co-develop, co-fund, or access complementary assets and trial sites.

European access expansion Launch of Keelira to provide early clinical development services in Europe signals availability of a local CRO/PMO and regional trial execution capability, enabling faster site activation and potential resourcing deals for oncology programs.

Clinical data visibility Regular presentations at major oncology conferences (EHA, ASH, AACR) on romaciclib (RVU120) enhance credibility and create openings for collaboration on multi-center trials, investigator-initiated studies, or strategic partnerships.

BioTech collaboration potential Active alliance with BioNTech to support trial site activation and patient recruitment in Poland highlights a potential repeat collaboration model for immuno-oncology programs and access to patient populations in Central Europe.